Zacks Research Has Positive View of Hologic FY2025 Earnings

Hologic, Inc. (NASDAQ:HOLX) – Zacks Research increased their FY2025 earnings per share estimates for Hologic in a research note issued to investors on Tuesday, August 19th. Zacks Research analyst Team now anticipates that the medical equipment provider will post earnings per share of $4.22 for the year, up from their prior forecast of $4.20. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic’s Q2 2026 earnings at $1.05 EPS, Q3 2026 earnings at $1.13 EPS, FY2026 earnings at $4.38 EPS, Q1 2027 earnings at $1.17 EPS, Q3 2027 earnings at $1.20 EPS and FY2027 earnings at $4.77 EPS.

A number of other equities research analysts have also recently commented on the company. Wall Street Zen upgraded Hologic from a “hold” rating to a “buy” rating in a research note on Friday. Mizuho set a $75.00 price objective on shares of Hologic in a research report on Thursday, July 31st. Needham & Company LLC reissued a “hold” rating on shares of Hologic in a research report on Tuesday, May 27th. Stephens decreased their price target on shares of Hologic from $77.00 to $70.00 and set an “overweight” rating for the company in a report on Tuesday, May 13th. Finally, Morgan Stanley lifted their price objective on shares of Hologic from $65.00 to $69.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $78.00.

Hologic Stock Up 1.6%

Hologic stock opened at $68.26 on Friday. Hologic has a 1-year low of $51.90 and a 1-year high of $84.39. The business has a fifty day moving average price of $65.90 and a 200-day moving average price of $62.49. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The stock has a market capitalization of $15.18 billion, a price-to-earnings ratio of 28.32, a PEG ratio of 2.44 and a beta of 0.49.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the firm posted $1.06 earnings per share. The company’s quarterly revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS.

Institutional Investors Weigh In On Hologic

Hedge funds have recently bought and sold shares of the stock. Farther Finance Advisors LLC increased its holdings in shares of Hologic by 22.3% during the 1st quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider’s stock valued at $113,000 after purchasing an additional 335 shares in the last quarter. SG Americas Securities LLC raised its position in shares of Hologic by 116.6% in the first quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider’s stock worth $594,000 after acquiring an additional 5,172 shares during the period. Brevan Howard Capital Management LP boosted its stake in shares of Hologic by 85.5% during the 4th quarter. Brevan Howard Capital Management LP now owns 19,436 shares of the medical equipment provider’s stock worth $1,401,000 after acquiring an additional 8,960 shares in the last quarter. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Hologic by 1.7% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 32,056 shares of the medical equipment provider’s stock worth $1,980,000 after acquiring an additional 528 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky grew its position in shares of Hologic by 4.5% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 17,945 shares of the medical equipment provider’s stock valued at $1,108,000 after acquiring an additional 767 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.